KL as A Potential Drug Target and Biomarker (G9365)

Target Name: KL

NCBI ID: G9365

Content of Review Report on KL Target / Biomarker

KL as A Potential Drug Target and Biomarker

KL (alpha-klotho), a protein produced by the liver, has been identified as a potential drug target and biomarker for the treatment of a range of diseases, including liver disease, cancer, and neurodegenerative disorders.

The protein KL is a key component of the liver's bile duct system, which is responsible for transporting bile from the liver to the small intestine. KL plays a crucial role in the production and secretion of bile, and its dysfunction has been linked to a number of diseases.

Research has shown that KL is involved in the regulation of bile acid levels, and that alterations in KL activity can have a significant impact on bile acid homeostasis. This is important, as bile acid levels are closely linked to a number of health conditions, including liver disease and certain cancers.

One of the key challenges in studying KL is its complex structure and the difficulty in recreating its natural function in a laboratory setting. However, researchers have been able to use various techniques to study its behavior in cell culture and animal models, and have made some promising discoveries.

One of the key functions of KL is its role in the regulation of cell growth and differentiation. In addition, KL has been shown to play a key role in the development and progression of cancer. Studies have shown that KL is highly expressed in many types of cancer, including breast, lung, and ovarian cancer.

In addition to its role in cancer, KL has also been linked to the development of neurodegenerative disorders. In research on ALS (Amyotrophic Lateral Sclerosis), a progressive neurodegenerative disorder, scientists have found that KL levels are significantly reduced in the brains of patients with the disease.

These findings suggest that KL may be a promising drug target and biomarker for the treatment of a range of neurodegenerative disorders, including ALS.

In addition to its potential use as a drug target, KL has also been identified as a potential biomarker for a number of diseases. For example, studies have shown that KL levels are significantly elevated in the blood of patients with heart disease, and that these levels are associated with increased risk of cardiac events.

In addition, KL has also been shown to be elevated in the blood of patients with liver disease, and that these levels are associated with increased risk of liver failure and other liver-related conditions.

These findings suggest that KL may also be a promising biomarker for the treatment of liver disease and other conditions.

In conclusion, KL is a protein that plays a crucial role in the regulation of bile duct system and has been linked to a number of diseases, including cancer and neurodegenerative disorders. While further research is needed to fully understand its potential as a drug target and biomarker, its promising findings suggest that it may be a valuable tool for the treatment of a range of diseases.

Protein Name: Klotho

Functions: May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By similarity). Essential factor for the specific interaction between FGF23 and FGFR1 (By similarity)

The "KL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets